
|Articles|May 29, 2012
Sanofi, Novo, Lilly Shape up for Big Insulin Fight
Advertisement
Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.
Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Deprescribing Antidepressants Safely: New Evidence Supports Gradual Taper With Therapy
3
T-DXd Regimens Show Better Tolerability, Manageable Safety in High-Risk, HER2-Positive Early Breast Cancer
4
Digital Innovation and New Drugs Converge to Transform CRM Care
5













































